U.S. Markets closed

Novartis AG (NVS)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
84.99-0.43 (-0.50%)
At close: 4:02PM EDT
People also watch
GSKSNYAZNLLYABT

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
http://www.novartis.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees118,000

Key Executives

NameTitlePayExercisedAge
Mr. Joseph Jimenez Jr., MBAChief Exec. OfficerN/AN/A58
Mr. Harry KirschChief Financial Officer2.82MN/A52
Mr. André WyssPres of Operations & Country Pres of Switzerland2.46MN/A50
Dr. Felix R. Ehrat Ph.D.Group Gen. CounselN/AN/A60
Mr. Steven BaertHead of HR2.22MN/A43
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segments also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. In addition, the company has a clinical research collaboration with Bristol-Myers Squibb Company to investigate Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist as a treatment option for metastatic colorectal cancer. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AG’s ISS Governance QualityScore as of July 1, 2017 is 7. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 9; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.